This study examined whether aqueous humor viral load (by PCR) and IL-8 levels (by ELISA) correlate with clinical outcomes in 43 ARN patients (53 eyes) treated with intravitreal ganciclovir, tracking changes over the course of antiviral therapy.
VZV was the causative agent in 92.5% of eyes. High initial VZV load (≥5.0 × 10⁶ copies/ml) predicted significantly worse baseline and final BCVA. Worse final BCVA correlated with higher baseline VZV DNA load (r = 0.14, p < 0.01) and higher IL-8 levels (r = 0.26, p < 0.01). After treatment, both markers declined following a plateau — viral load plateaued for ~2 weeks vs. ~1 week for IL-8 — and their changes were positively correlated (r = 0.33, p < 0.01).
- Small, single-center cohort (43 patients, 53 eyes) limits generalizability. - No significant overall BCVA improvement from baseline to final follow-up (p = 0.43), raising questions about treatment efficacy or follow-up duration. - Correlation coefficients are modest (r = 0.14–0.33), suggesting viral load and IL-8 explain only a fraction of visual outcome variance.
In ARN patients, measuring aqueous IL-8 alongside viral load may give an earlier read on antiviral treatment response, since IL-8 plateaus resolve roughly one week sooner than viral load plateaus. Clinicians should consider high baseline VZV load (≥5.0 × 10⁶ copies/ml) a marker of poorer visual prognosis.
Explore related topics